Literature DB >> 15598989

IgG(4) Pf NPNA-1 a human anti-Plasmodium falciparum sporozoite monoclonal antibody cloned from a protected individual inhibits parasite invasion of hepatocytes.

Jonathan A Chappel1, Michael R Hollingdale, Angray S Kang.   

Abstract

Malaria is one of the world's most devastating diseases, and Plasmodium falciparum (Pf) causes significant mortalities particularly in Sub-Saharan Africa. The rise and spread of multi-drug resistant strains of the parasite has coincided with an era of increased travel to malaria endemic regions. In the absence of an effective vaccine against malaria it may be possible to utilize human monoclonal antibodies against the stage transmitted by mosquito bites (sporozoites) as a prophylactic to prevent infection. We report the characterization of an engineered human IgG(4) monoclonal antibody against Pf sporozoite cloned from a protected individual recognized the sporozoite surface and inhibited sporozoite invasion of human hepatocytes in vitro. The fully human monoclonal antibody PfNPNA-1 IgG(4) against (NPNA)(3) specifically labels Plasmodium falciparum in an IFA. This antibody also inhibits Plasmodium falciparum sporozoite invasion of human hepatocytes HepG2-A16 in a dose dependent manner in an in vitro assay. PfNPNA-1 IgG(4) is a promising candidate for evaluation for the prevention of malaria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15598989

Source DB:  PubMed          Journal:  Hum Antibodies        ISSN: 1093-2607


  8 in total

1.  Using infections to fight infections: paratransgenic fungi can block malaria transmission in mosquitoes.

Authors:  Jason L Rasgon
Journal:  Future Microbiol       Date:  2011-08       Impact factor: 3.165

2.  A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.

Authors:  Anjali Yadava; Jetsumon Sattabongkot; Michael A Washington; Lisa A Ware; Victoria Majam; Hong Zheng; Sanjai Kumar; Christian F Ockenhouse
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

3.  Circumsporozoite protein as a potential target for antimalarials.

Authors:  Cristina Fernández-Arias; Sara Mashoof; Jing Huang; Moriya Tsuji
Journal:  Expert Rev Anti Infect Ther       Date:  2015-06-16       Impact factor: 5.091

4.  Ribosome display of combinatorial antibody libraries derived from mice immunized with heat-killed Xylella fastidiosa and the selection of MopB-specific single-chain antibodies.

Authors:  Armaghan Azizi; Arinder Arora; Anatoliy Markiv; David J Lampe; Thomas A Miller; Angray S Kang
Journal:  Appl Environ Microbiol       Date:  2012-02-10       Impact factor: 4.792

5.  Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites.

Authors:  Olivia C Finney; Gladys J Keitany; Hannah Smithers; Alexis Kaushansky; Stefan Kappe; Ruobing Wang
Journal:  Vaccine       Date:  2014-02-28       Impact factor: 3.641

6.  Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1.

Authors:  Dominika J Maskus; Michał Królik; Susanne Bethke; Holger Spiegel; Stephanie Kapelski; Melanie Seidel; Otchere Addai-Mensah; Andreas Reimann; Torsten Klockenbring; Stefan Barth; Rainer Fischer; Rolf Fendel
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

7.  Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis.

Authors:  Sidhartha Chaudhury; Jason A Regules; Christian A Darko; Sheetij Dutta; Anders Wallqvist; Norman C Waters; Erik Jongert; Franck Lemiale; Elke S Bergmann-Leitner
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

8.  Characterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals.

Authors:  Thanh V Nguyen; John B Sacci; Patricia de la Vega; Chandy C John; Anthony A James; Angray S Kang
Journal:  Malar J       Date:  2009-10-23       Impact factor: 2.979

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.